Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ibritumomab tiuxetan
Drug ID BADD_D01118
Description Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
Indications and Usage For treatment of non-Hodgkin's lymphoma
Marketing Status approved; investigational
ATC Code Not Available
DrugBank ID DB00078
KEGG ID D04489
MeSH ID C422802
PubChem ID 92002593
TTD Drug ID Not Available
NDC Product Code 72893-007
UNII 4Q52C550XK
Synonyms ibritumomab tiuxetan | Zevalin | yttrium-90-ibritumomab tiuxetan | IDEC-Y2B8 | IDEC-Y2B8 IDEC-129 | IDEC-129
Chemical Information
Molecular Formula C24H35N5O11
CAS Registry Number 206181-63-7
SMILES CC(CN(CC(CC1=CC=C(C=C1)NC(=O)NC)N(CC(=O)O)CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sinusitis22.07.03.007; 11.01.13.005--
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Thrombocytopenia01.08.01.002--Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.006--
Ulcer08.03.06.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Infusion site erythema23.03.06.016; 12.07.05.009; 08.02.05.008--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
The 2th Page    First    Pre   2    Total 2 Pages